Autoimmune dysregulation and purine metabolism in adenosine deaminase deficiency

Frontiers in Immunology

Volumn 3, Issue AUG, 2012, Pages

  Sauer, AishaVanessa ^a   Brigida, Immacolata ^a   Carriglio, Nicola ^a,b   Aiuti, Alessandro ^a,b  

^a SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

ADA SCID; Adenosine deaminase; Autoimmunity; Gene therapy; Severe combined immunodeficiency

Indexed keywords

EID: 84874222136     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2012.00265     Document Type: Article

References (143)

1. Abuchowski, A., van Es, T., Palczuk, N. C., and Davis, F. F. (1977). Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J. Biol. Chem. 252, 3578-3581.
2. Aiuti, A. (2004). Gene therapy for adenosine-deaminase-deficient severe combined immunodeficiency. Best Pract. Res. Clin. Haematol. 17, 505-516.
3. Aiuti, A., Cassani, B., Andolfi, G., Mirolo, M., Biasco, L., Recchia, A., Urbinati, F., Valacca, C., Scaramuzza, S., Aker, M., Slavin, S., Cazzola, M., Sartori, D., Ambrosi, A., Di Serio, C., Roncarolo, M. G., Mavilio, F., and Bordignon, C. (2007). Multilineage hematopoietic reconstitution without clonal selection in ADASCID patients treated with stem cell gene therapy. J. Clin. Invest. 117, 2233-2240.
4. Aiuti, A., Cattaneo, F., Galimberti, F., Benninghoff, U., Cassani, B., Callegaro, L., Scaramuzza, S., Andolfi, G., Mirolo, M., Brigida, I., Tabucchi, A., Carlucci, F., Eibl, M., Aker, M., Slavin, S., Al-Mousa, H., Al Ghonaium, A., Ferster, A., Duppenthaler, A., Notarangelo, L., Wintergerst, U., Buckley, R., Bregni, M., Valsecchi, M., Rossi, P., Ciceri, F., Miniero, R., Bordignon, C., and Roncarolo, M. (2009). Long-term safety and efficacy of gene therapy for adenosine deaminase (ADA)deficient severe combined immunodeficiency. N. Engl. J. Med. 360, 447-458.
5. Aiuti, A., Ficara, F., Cattaneo, F., Bordignon, C., and Roncarolo, M. G. (2003). Gene therapy for adenosine deaminase deficiency. Curr. Opin. Allergy Clin. Immunol. 3, 461-466.
6. Aldrich, M. B., Chen, W., Blackburn, M. R., Martinez-Valdez, H., Datta, S. K., and Kellems, R. E. (2003). Impaired germinal center maturation in adenosine deaminase deficiency. J. Immunol. 171, 5562-5570.
7. Antoine, C., Muller, S., Cant, A., Cavazzana-Calvo, M., Veys, P., Vossen, J., Fasth, A., Heilmann, C., Wulffraat, N., Seger, R., Blanche, S., Friedrich, W., Abinun, M., Davies, G., Bredius, R., Schulz, A., Landais, P., and Fischer, A. (2003). Longterm survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-1999. Lancet 361, 553-560.
8. Apasov, S. G., Blackburn, M. R., Kellems, R. E., Smith, P. T., and Sitkovsky, M. V. (2001). Adenosine deaminase deficiency increases thymic apoptosis and causes defective T cell receptor signaling. J. Clin. Invest. 108, 131-141.
9. Apasov, S. G., and Sitkovsky, M. V. (1999). The extracellular versus intracellular mechanisms of inhibition of TCR-triggered activation in thymocytes by adenosine under conditions of inhibited adenosine deaminase. Int. Immunol. 11, 179-189.
10. Bach, J. F. (2003). Regulatory T cells under scrutiny. Nat. Rev. Immunol. 3, 189-198.
11. Barsalou, J., Saint-Cyr, C., Drouin, E., Le Deist, F., and Haddad, E. (2011). High prevalence of primary immune deficiencies in children with autoimmune disorders. Clin. Exp. Rheumatol. 29, 125-130.
12. Belardinelli, L., Linden, J., and Berne, R. M. (1989). The cardiac effects of adenosine. Prog. Cardiovasc. Dis. 32, 73-97.
13. Benveniste, P., Zhu, W., and Cohen, A. (1995). Interference with thymocyte differentiation by an inhibitor of Sadenosylhomocysteine hydrolase. J. Immunol. 155, 536-544.
14. Blackburn, M. R. (2003). Too much of a good thing: adenosine overload in adenosine-deaminase-deficient mice. Trends Pharmacol. Sci. 24, 66-70.
15. Blackburn, M. R., Aldrich, M., Volmer, J. B., Chen, W., Zhong, H., Kelly, S., Hershfield, M. S., Datta, S. K., and Kellems, R. E. (2000). The use of enzyme therapy to regulate the metabolic and phenotypic consequences of adenosine deaminase deficiency in mice. Differential impact on pulmonary and immunologic abnormalities. J. Biol. Chem. 275, 32114-32121.
16. Blackburn, M. R., Datta, S. K., and Kellems, R. E. (1998). Adenosine deaminase-deficient mice generated using a two-stage genetic engineering strategy exhibit a combined immunodeficiency. J. Biol. Chem. 273, 5093-5100.
17. Bollinger, M. E., Arredondo-Vega, F. X., Santisteban, I., Schwarz, K., Hershfield, M. S., and Lederman, H. M. (1996). Brief report: hepatic dysfunction as a complication of adenosine deaminase deficiency. N. Engl. J. Med. 334, 1367-1371.
18. Booth, C., and Gaspar, H. B. (2009). Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID). Biologics 3, 349-358.
19. Booth, C., Hershfield, M., Notarangelo, L., Buckley, R., Hoenig, M., Mahlaoui, N., Cavazzana-Calvo, M., Aiuti, A., and Gaspar, H. B. (2007). Management options for adenosine deaminase deficiency; proceedings of the EBMT satellite workshop (Hamburg, March 2006). Clin. Immunol. 123, 139-147.
20. Bordignon, C., and Roncarolo, M. G. (2002). Therapeutic applications for hematopoietic stem cell gene transfer. Nat. Immunol. 3, 318-321.
21. Borsellino, G., Kleinewietfeld, M., Di Mitri, D., Sternjak, A., Diamantini, A., Giometto, R., Hopner, S., Centonze, D., Bernardi, G., Dell'acqua, M. L., Rossini, P. M., Battistini, L., Rotzschke, O., and Falk, K. (2007). Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 110, 1225-1232.
22. Buckley, R. H., Schiff, R. I., Schiff, S. E., Markert, M. L., Williams, L. W., Harville, T. O., Roberts, J. L., and Puck, J. M. (1997). Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. J. Pediatr. 130, 378-387.
23. Cancrini, C., Ferrua, F., Scarselli, A., Brigida, I., Romiti, M. L., Barera, G., Finocchi, A., Roncarolo, M. G., Caniglia, M., and Aiuti, A. (2010). Role of reduced intensity conditioning in T-cell and B-cell immune reconstitution after HLAidentical bone marrow transplantation in ADA-SCID. Haematologica 95, 1778-1782.
24. Cancro, M. P. (2009). Signalling crosstalk in B cells: managing worth and need. Nat. Rev. Immunol. 9, 657-661.
25. Carneiro-Sampaio, M., and Coutinho, A. (2007). Tolerance and autoimmunity: lessons at the bedside of primary immunodeficiencies. Adv. Immunol. 95, 51-82.
26. Cassani, B., Mirolo, M., Cattaneo, F., Benninghoff, U., Hershfield, M., Carlucci, F., Tabucchi, A., Bordignon, C., Roncarolo, M. G., and Aiuti, A. (2008). Altered intracellular and extracellular signaling leads to impaired T-cell functions in ADA-SCID patients. Blood 111, 4209-4219.
27. Chaffee, S., Mary, A., Stiehm, E. R., Girault, D., Fischer, A., and Hershfield, M. S. (1992). IgG antibody response to polyethylene glycolmodified adenosine deaminase in patients with adenosine deaminase deficiency. J. Clin. Invest. 89, 1643-1651.
28. Chan, B., Wara, D., Bastian, J., Hershfield, M. S., Bohnsack, J., Azen, C. G., Parkman, R., Weinberg, K., and Kohn, D. B. (2005). Longterm efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID). Clin. Immunol. 117, 133-143.
29. Churchill, P. C., and Bidani, A. K. (1982). Hypothesis: adenosine mediates hemodynamic changes in renal failure. Med. Hypotheses 8, 275-285.
30. Cohen, A., and Thompson, E. (1986). DNA repair in nondividing human lymphocytes: inhibition by deoxyadenosine. Cancer Res. 46, 1585-1588.
31. Cunningham-Rundles, C. (2011). Autoimmunity in primary immune deficiency: taking lessons from our patients. Clin. Exp. Immunol. 164(Suppl. 2), 6-11.
32. Cuss, A. K., Avery, D. T., Cannons, J. L., Yu, L. J., Nichols, K. E., Shaw, P. J., and Tangye, S. G. (2006). Expansion of functionally immature transitional B cells is associated with humanimmunodeficient states characterized by impaired humoral immunity. J. Immunol. 176, 1506-1516.
33. Daikeler, T., and Tyndall, A. (2007). Autoimmunity following haematopoietic stem-cell transplantation. Best Pract. Res. Clin. Haematol. 20, 349-360.
34. Dave, U. P., Akagi, K., Tripathi, R., Cleveland, S. M., Thompson, M. A., Yi, M., Stephens, R., Downing, J. R., Jenkins, N. A., and Copeland, N. G. (2009). Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCIDX1 patients following retroviral gene therapy. PLoS Genet. 5, e1000491. doi:10.1371/journal.pgen.1000491
35. Davis, S., Abuchowski, A., Park, Y. K., and Davis, F. F. (1981). Alteration of the circulating life and antigenic properties of bovine adenosine deaminase in mice by attachment of polyethylene glycol. Clin. Exp. Immunol. 46, 649-652.
36. Deaglio, S., Dwyer, K. M., Gao, W., Friedman, D., Usheva, A., Erat, A., Chen, J. F., Enjyoji, K., Linden, J., Oukka, M., Kuchroo, V. K., Strom, T. B., and Robson, S. C. (2007). Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204, 1257-1265.
37. Elliott, M. R., Chekeni, F. B., Trampont, P. C., Lazarowski, E. R., Kadl, A., Walk, S. F., Park, D., Woodson, R. I., Ostankovich, M., Sharma, P., Lysiak, J. J., Harden, T. K., Leitinger, N., and Ravichandran, K. S. (2009). Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 461, 282-286.
38. Erdmann, A. A., Gao, Z. G., Jung, U., Foley, J., Borenstein, T., Jacobson, K. A., and Fowler, D. H. (2005). Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2driven expansion in vivo. Blood 105, 4707-4714.
39. Etzioni, A. (2003). Immune deficiency and autoimmunity. Autoimmun. Rev. 2, 364-369.
40. Ferrua, F., Brigida, I., and Aiuti, A. (2010). Update on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency. Curr. Opin. Allergy Clin. Immunol. 10, 551-556.
41. Fischer, A., Le Deist, F., Hacein-BeyAbina, S., Andre-Schmutz, I., Basile Gde, S., De Villartay, J. P., and Cavazzana-Calvo, M. (2005). Severe combined immunodeficiency. A model disease for molecular immunology and therapy. Immunol. Rev. 203, 98-109.
42. Fredholm, B. B., and Dunwiddie, T. V. (1988). How does adenosine inhibit transmitter release? Trends Pharmacol. Sci. 9, 130-134.
43. Fukunaga, A. F., Flacke, W. E., and Bloor, B. C. (1982). Hypotensive effects of adenosine and adenosine triphosphate compared with sodium nitroprusside. Anesth. Analg. 61, 273-278.
44. Gaipl, U. S., Sheriff, A., Franz, S., Munoz, L. E., Voll, R. E., Kalden, J. R., and Herrmann, M. (2006). Inefficient clearance of dying cells and autoreactivity. Curr. Top. Microbiol. Immunol. 305, 161-176.
45. Gangi-Peterson, L., Sorscher, D. H., Reynolds, J. W., Kepler, T. B., and Mitchell, B. S. (1999). Nucleotide pool imbalance and adenosine deaminase deficiency induce alterations of N-region insertions during V(D)J recombination. J. Clin. Invest. 103, 833-841.
46. Gaspar, H. B., Aiuti, A., Porta, F., Candotti, F., Hershfield, M. S., and Notarangelo, L. D. (2009). How I treat ADA deficiency. Blood 114, 3524-3532.
47. Gaspar, H. B., Cooray, S., Gilmour, K. C., Parsley, K. L., Zhang, F., Adams, S., Bjorkegren, E., Bayford, J., Brown, L., Davies, E. G., Veys, P., Fairbanks, L., Bordon, V., Petropolou, T., Kinnon, C., and Thrasher, A. J. (2011). Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci. Transl. Med. 3, 97ra80.
48. Giblett, E. R., Anderson, J. E., Cohen, F., Pollara, B., and Meuwissen, H. J. (1972). Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 2, 1067-1069.
49. Goodnow, C. C. (1996). Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires. Proc. Natl. Acad. Sci. U.S.A. 93, 2264-2271.
50. Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., Asnafi, V., Macintyre, E., Dal Cortivo, L., Radford, I., Brousse, N., Sigaux, F., Moshous, D., Hauer, J., Borkhardt, A., Belohradsky, B. H., Wintergerst, U., Velez, M. C., Leiva, L., Sorensen, R., Wulffraat, N., Blanche, S., Bushman, F. D., Fischer, A., and Cavazzana-Calvo, M. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 118, 3132-3142.
51. Hasko, G., Linden, J., Cronstein, B., and Pacher, P. (2008). Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat. Rev. Drug Discov. 7, 759-770.
52. Hassan, A., Booth, C., Brightwell, A., Allwood, Z., Veys, P., Rao, K., Honig, M., Friedrich, W., Gennery, A., Slatter, M., Bredius, R., Finocchi, A., Cancrini, C., Aiuti, A., Porta, F., Lanfranchi, A., Ridella, M., Steward, C., Filipovich, A., Marsh, R., Bordon, V., Al-Muhsen, S., Al-Mousa, H., Alsum, Z., AlDhekri, H., Al Ghonaium, A., Speckmann, C., Fischer, A., Mahlaoui, N., Nichols, K. E., Grunebaum, E., Al Zahrani, D., Roifman, C. M., Boelens, J., Davies, E. G., Cavazzana-Calvo, M., Notarangelo, L., and Gaspar, H. B. (2012). Outcome of hematopoietic stem cell transplantation for adenosine deaminase deficient severe combined immunodeficiency. Blood. doi:10.1182/blood2011-12-396879. [Epub ahead of print].
53. Hauri-Hohl, M. M., Keller, M. P., Gill, J., Hafen, K., Pachlatko, E., Boulay, T., Peter, A., Hollander, G. A., and Krenger, W. (2007). Donor T-cell alloreactivity against host thymic epithelium limits T-cell development after bone marrow transplantation. Blood 109, 4080-4088.
54. Hershfield, M. (2005). New insights into adenosine-receptor-mediated immunosuppression and the role of adenosine in causing the immunodeficiency associated with adenosine deaminase deficiency. Eur. J. Immunol. 35, 25-30.
55. Hershfield, M. S. (1995). PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years. Clin. Immunol. Immunopathol. 76, S228-S232.
56. Hershfield, M. S., Buckley, R. H., Greenberg, M. L., Melton, A. L., Schiff, R., Hatem, C., Kurtzberg, J., Markert, M. L., Kobayashi, R. H., Kobayashi, A. L., and Abuchowski, A. (1987). Treatment of adenosine deaminase deficiency with polyethylene glycolmodified adenosine deaminase. N. Engl. J. Med. 316, 589-596.
57. Hershfield, M. S., Kredich, N. M., Ownby, D. R., Ownby, H., and Buckley, R. (1979). In vivo inactivation of erythrocyte Sadenosylhomocysteine hydrolase by 2'-deoxyadenosine in adenosine deaminase-deficient patients. J. Clin. Invest. 63, 807-811.
58. Hill, N. J., Hultcrantz, M., Sarvetnick, N., andFlodstrom-Tullberg, M. (2007). The target tissue in autoimmunity - an influential niche. Eur. J. Immunol. 37, 589-597.
59. Hirschhorn, R., and Candotti, F. (2006). "Immunodeficiency due to defects of purine metabolism," in Primary Immunodeficiency Diseases, eds H. D. Ochs, C. I. E. Smith, and J. M. Puck (Oxford: Oxford University Press), 169-196.
60. Hirschhorn, R., Nicknam, M. N., Eng, F., Yang, D. R., and Borkowsky, W. (1992). Novel deletion and a new missense mutation (Glu 217 Lys) at the catalytic site in two adenosine deaminase alleles of a patient with neonatal onset adenosine deaminase - severe combined immunodeficiency. J. Immunol. 149, 3107-3112.
61. Hirschhorn, R., and Ratech, H. (1980). Isozymes of adenosine deaminase. Isozymes Curr. Top. Biol. Med. Res. 4, 131-157.
62. Honig, M., Albert, M. H., Schulz, A., Sparber-Sauer, M., Schutz, C., Belohradsky, B., Gungor, T., Rojewski, M. T., Bode, H., Pannicke, U., Lippold, D., Schwarz, K., Debatin, K. M., Hershfield, M. S., and Friedrich, W. (2007). Patients with adenosine deaminase deficiency surviving after hematopoietic stem cell transplantation are at high risk of CNS complications. Blood 109, 3595-3602.
63. Howe, S. J., Mansour, M. R., Schwarzwaelder, K., Bartholomae, C., Hubank, M., Kempski, H., Brugman, M. H., Pike-Overzet, K., Chatters, S. J., de Ridder, D., Gilmour, K. C., Adams, S., Thornhill, S. I., Parsley, K. L., Staal, F. J., Gale, R. E., Linch, D. C., Bayford, J., Brown, L., Quaye, M., Kinnon, C., Ancliff, P., Webb, D. K., Schmidt, M., Von Kalle, C., Gaspar, H. B., and Thrasher, A. J. (2008). Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest. 118, 3143-3150.
64. Huang, S., Apasov, S., Koshiba, M., and Sitkovsky, M. (1997). Role of A2a extracellular adenosine receptormediated signaling in adenosinemediated inhibition of T-cell activation and expansion. Blood 90, 1600-1610.
65. Isnardi, I., Ng, Y. S., Srdanovic, I., Motaghedi, R., Rudchenko, S., Von Bernuth, H., Zhang, S. Y., Puel, A., Jouanguy, E., Picard, C., Garty, B. Z., Camcioglu, Y., Doffinger, R., Kumararatne, D., Davies, G., Gallin, J. I., Haraguchi, S., Day, N. K., Casanova, J. L., and Meffre, E. (2008). IRAK-4and MyD88dependent pathways are essential for the removal of developing autoreactive B cells in humans. Immunity 29, 746-757.
66. Junger, W. G. (2011). Immune cell regulation by autocrine purinergic signalling. Nat. Rev. Immunol. 11, 201-212.
67. Kameoka, J., Tanaka, T., Nojima, Y., Schlossman, S. F., and Morimoto, C. (1993). Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science 261, 466-469.
68. Klein, L., Hinterberger, M., Wirnsberger, G., and Kyewski, B. (2009). Antigen presentation in the thymus for positive selection and central tolerance induction. Nat. Rev. Immunol. 9, 833-844.
69. Kohn, D. B. (1996). Gene therapy for hematopoietic and immune disorders. Bone Marrow Transplant. 18(Suppl. 3), S55-S58.
70. Kohn, D. B. (2008). Gene therapy for childhood immunological diseases. Bone Marrow Transplant. 41, 199-205.
71. Koller, C. A., Orringer, E. P., Berkowitz, L. R., and Mulhern, A. T. (1984). Role of glycolysis in deoxyadenosine induced ATP depletion and dATP accumulation in red cells. Prog. Clin. Biol. Res. 165, 227-239.
72. Kono, D. H., Haraldsson, M. K., Lawson, B. R., Pollard, K. M., Koh, Y. T., Du, X., Arnold, C. N., Baccala, R., Silverman, G. J., Beutler, B. A., and Theofilopoulos, A. N. (2009). Endosomal TLR signaling is required for anti-nucleic acid and rheumatoid factor autoantibodies in lupus. Proc. Natl. Acad. Sci. U.S.A. 106, 12061-12066.
73. Lainka, E., Hershfield, M. S., Santisteban, I., Bali, P., Seibt, A., Neubert, J., Friedrich, W., and Niehues, T. (2005). polyethylene glycol-conjugated adenosine deaminase (ADA) therapy provides temporary immune reconstitution to a child with delayed-onset ADA deficiency. Clin. Diagn. Lab. Immunol. 12, 861-866.
74. Lappas, C. M., Rieger, J. M., and Linden, J. (2005). A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells. J. Immunol. 174, 1073-1080.
75. Levy, Y., Hershfield, M. S., Fernandez Mejia, C., Polmar, S. H., Scudiery, D., Berger, M., and Sorensen, R. U. (1988). Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase. J. Pediatr. 113, 312-317.
76. Liao, H., Hyman, M. C., Baek, A. E., Fukase, K., and Pinsky, D. J. (2010). cAMP/CREB-mediated transcriptional regulation of ectonucleoside triphosphate diphosphohydrolase 1 (CD39) expression. J. Biol. Chem. 285, 14791-14805.
77. Luning Prak, E. T. (2012). Restoring balance to B cells in ADA deficiency. J. Clin. Invest. 122, 1960-1962.
78. Malacarne, F., Benicchi, T., Notarangelo, L. D., Mori, L., Parolini, S., Caimi, L., Hershfield, M., and Imberti, L. (2005). Reduced thymic output, increased spontaneous apoptosis and oligoclonal B cells in polyethylene glycol-adenosine deaminasetreated patients. Eur. J. Immunol. 35, 3376-3386.
79. Mandapathil, M., Hilldorfer, B., Szczepanski, M. J., Czystowska, M., Szajnik, M., Ren, J., Lang, S., Jackson, E. K., Gorelik, E., and Whiteside, T. L. (2010). Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells(TREG). J. Biol. Chem. 285, 7176-7186.
80. Marshak-Rothstein, A. (2006). Tolllike receptors in systemic autoimmune disease. Nat. Rev. Immunol. 6, 823-835.
81. Mathis, D., and Benoist, C. (2004). Back to central tolerance. Immunity 20, 509-516.
82. Mazzolari, E., de Martiis, D., Forino, C., Lanfranchi, A., Giliani, S., Marzollo, R., Airo, P., Imberti, L., Porta, F., and Notarangelo, L. D. (2009). Singlecenter analysis of long-term outcome after hematopoietic cell transplantation in children with congenital severe T cell immunodeficiency. Immunol. Res. 44, 4-17.
83. Meffre, E. (2012). The establishment of early B cell tolerance in humans: lessons from primary immunodeficiency diseases. Ann. N. Y. Acad. Sci. 1246, 1-10.
84. Meffre, E., and Wardemann, H. (2008). B-cell tolerance checkpoints in health and autoimmunity. Curr. Opin. Immunol. 20, 632-638.
85. Menard, L., Saadoun, D., Isnardi, I., Ng, Y. S., Meyers, G., Massad, C., Price, C., Abraham, C., Motaghedi, R., Buckner, J. H., Gregersen, P. K., and Meffre, E. (2011). The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. J. Clin. Invest. 121, 3635-3644.
86. Minguet, S., Huber, M., Rosenkranz, L., Schamel, W. W., Reth, M., and Brummer, T. (2005). Adenosine and cAMP are potent inhibitors of the NF-kappa B pathway downstream of immunoreceptors. Eur. J. Immunol. 35, 31-41.
87. Montiel-Equihua, C. A., Thrasher, A. J., and Gaspar, H. B. (2012). Gene therapy for severe combined immunodeficiency due to adenosine deaminase deficiency. Curr. Gene Ther. 12, 57-65.
88. Moratto, D., Giliani, S., Bonfim, C., Mazzolari, E., Fischer, A., Ochs, H. D., Cant, A. J., Thrasher, A. J., Cowan, M. J., Albert, M. H., Small, T., Pai, S. Y., Haddad, E., Lisa, A., Hambleton, S., Slatter, M., Cavazzana-Calvo, M., Mahlaoui, N., Picard, C., Torgerson, T. R., Burroughs, L., Koliski, A., Neto, J. Z., Porta, F., Qasim, W., Veys, P., Kavanau, K., Honig, M., Schulz, A., Friedrich, W., and Notarangelo, L. D. (2011). Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study. Blood 118, 1675-1684.
89. Morgan, G., Levinsky, R. J., Hugh-Jones, K., Fairbanks, L. D., Morris, G. S., and Simmonds, H. A. (1987). Heterogeneity of biochemical, clinical and immunological parameters in severe combined immunodeficiency due to adenosine deaminase deficiency. Clin. Exp. Immunol. 70, 491-499.
90. Mortellaro, A., Jofra Hernandez, R., Guerrini, M. M., Carlucci, F., Tabucchi, A., Ponzoni, M., Sanvito, F., Doglioni, C., Di Serio, C., Biasco, L., Follenzi, A., Naldini, L., Bordignon, C., Roncarolo, M. G., and Aiuti, A. (2006). Ex vivo gene therapy with lentiviral vectors rescues adenosine deaminase (ADA)deficient mice and corrects their immune and metabolic defects. Blood 108, 2979-2988.
91. Nemazee, D., Kouskoff, V., Hertz, M., Lang, J., Melamed, D., Pape, K., and Retter, M. (2000). B-cell-receptordependent positive and negative selection in immature B cells. Curr. Top. Microbiol. Immunol. 245,57-71.
92. Neven, B., Leroy, S., Decaluwe, H., Le Deist, F., Picard, C., Moshous, D., Mahlaoui, N., Debre, M., Casanova, J. L., Dal Cortivo, L., Madec, Y., Hacein-Bey-Abina, S., De Saint Basile, G., De Villartay, J. P., Blanche, S., Cavazzana-Calvo, M., and Fischer, A. (2009). Long-term outcome after haematopoietic stem cell transplantation of a single-centre cohort of 90 patients with severe combined immunodeficiency: long-term outcome of HSCT in SCID. Blood 113, 4114-4124.
93. Ng, Y. S., Wardemann, H., Chelnis, J., Cunningham-Rundles, C., and Meffre, E. (2004). Bruton's tyrosine kinase is essential for human B cell tolerance. J. Exp. Med. 200, 927-934.
94. Notarangelo, L. D. (2009). Primary immunodeficiencies (PIDs) presenting with cytopenias. Hematology Am. Soc. Hematol. Educ. Program 2009, 139-143.
95. Notarangelo, L. D., Stoppoloni, G., Toraldo, R., Mazzolari, E., Coletta, A., Airo, P., Bordignon, C., and Ugazio, A. G. (1992). Insulindependent diabetes mellitus and severe atopic dermatitis in a child with adenosine deaminase deficiency. Eur. J. Pediatr. 151, 811-814.
96. Ochs, H. D., Buckley, R. H., Kobayashi, R. H., Kobayashi, A. L., Sorensen, R. U., Douglas, S. D., Hamilton, B. L., and Hershfield, M. S. (1992). Antibody responses to bacteriophage phi X174 in patients with adenosine deaminase deficiency. Blood 80, 1163-1171.
97. Ohta, A., Madasu, M., Kini, R., Subramanian, M., Goel, N., and Sitkovsky, M. (2009). A2A adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments. J. Immunol. 183, 5487-5493.
98. Olah, M. E., and Stiles, G. L. (1995). Adenosine receptor subtypes: characterization and therapeutic regulation. Annu. Rev. Pharmacol. Toxicol. 35, 581-606.
99. Ott, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kuhlcke, K., Schilz, A., Kunkel, H., Naundorf, S., Brinkmann, A., Deichmann, A., Fischer, M., Ball, C., Pilz, I., Dunbar, C., Du, Y., Jenkins, N. A., Copeland, N. G., Luthi, U., Hassan, M., Thrasher, A. J., Hoelzer, D., Von Kalle, C., Seger, R., and Grez, M. (2006). Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med. 12, 401-409.
100. Ozsahin, H., Arredondo-Vega, F. X., Santisteban, I., Fuhrer, H., Tuchschmid, P., Jochum, W., Aguzzi, A., Lederman, H. M., Fleischman, A., Winkelstein, J. A., Seger, R. A., and Hershfield, M. S. (1997). Adenosine deaminase deficiency in adults. Blood 89, 2849-2855.
101. Panther, E., Corinti, S., Idzko, M., Herouy, Y., Napp, M., La Sala, A., Girolomoni, G., and Norgauer, J. (2003). Adenosine affects expression of membrane molecules, cytokine and chemokine release, and the T-cell stimulatory capacity of human dendritic cells. Blood 101, 3985-3990.
102. Parish, I. A., and Heath, W. R. (2008). Too dangerous to ignore: selftolerance and the control of ignorant autoreactive T cells. Immunol. Cell Biol. 86, 146-152.
103. Park, J. Y., Shcherbina, A., Rosen, F. S., Prodeus, A. P., and RemoldO'Donnell, E. (2005). Phenotypic perturbation of B cells in the Wiskott-Aldrich syndrome. Clin. Exp. Immunol. 139, 297-305.
104. Parkman, R., Gelfand, E. W., Rosen, F. S., Sanderson, A., and Hirschhorn, R. (1975). Severe combined immunodeficiency and adenosine deaminase deficiency. N. Engl. J. Med. 292, 714-719.
105. Piccirillo, C. A., and Thornton, A. M. (2004). Cornerstone of peripheral tolerance: naturally occurring CD4+CD25+ regulatory T cells. Trends Immunol. 25, 374-380.
106. Poliani, P. L., Vermi, W., and Facchetti, F. (2009). Thymus microenvironment in human primary immunodeficiency diseases. Curr. Opin. Allergy Clin. Immunol. 9, 489-495.
107. Power Coombs, M. R., Belderbos, M. E., Gallington, L. C., Bont, L., and Levy, O. (2011). Adenosine modulates Toll-like receptor function: basic mechanisms and translational opportunities. Expert Rev. Anti. Infect. Ther. 9, 261-269.
108. Ratech, H., Hirschhorn, R., and Greco, M. A. (1989). Pathologic findings in adenosine deaminase deficient-severe combined immunodeficiency. II. Thymus, spleen, lymph node, and gastrointestinal tract lymphoid tissue alterations. Am. J. Pathol. 135, 1145-1156.
109. Ratter, F., Germer, M., Fischbach, T., Schulze-Osthoff, K., Peter, M. E., Droge, W., Krammer, P. H., and Lehmann, V. (1996). S-adenosylhomocysteine as a physiological modulator of Apo-1mediated apoptosis. Int. Immunol. 8, 1139-1147.
110. Rogers, M. H., Lwin, R., Fairbanks, L., Gerritsen, B., and Gaspar, H. B. (2001). Cognitive and behavioral abnormalities in adenosine deaminase deficient severe combined immunodeficiency. J. Pediatr. 139, 44-50.
111. Saccucci, P., Manca Bitti, M. L., Bottini, N., Rapini, N., Piccinini, S., D'Annibale, F., Chiarelli, F., Verrotti, A., Bottini, E., and Gloria-Bottini, F. (2009). Type 1 diabetes: evidence of interaction between ACP1 and ADA1 gene polymorphisms. Med. Sci. Monit. 15, CR511-C517.
112. Sakaguchi, S. (2005). Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 6, 345-352.
113. Sakaguchi, S., Yamaguchi, T., Nomura, T., and Ono, M. (2008). Regulatory T cells and immune tolerance. Cell 133, 775-787.
114. Sauer, A. V., and Aiuti, A. (2009). New insights into the pathogenesis of adenosine deaminase-severe combined immunodeficiency and progress in gene therapy. Curr. Opin. Allergy Clin. Immunol. 9, 496-502.
115. Sauer, A. V., Brigida, I., Carriglio, N., Jofra Hernandez, R., Scaramuzza, S., Clavenna, D., Sanvito, F., Poliani, P. L., Gagliani, N., Carlucci, F., Tabucchi, A., Roncarolo, M. G., Traggiai, E., Villa, A., and Aiuti, A. (2012a). Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID. Blood 119, 1428-1439.
116. Sauer, A. V., Morbach, H., Brigida, I., Ng, Y. S., Aiuti, A., and Meffre, E. (2012b). Defective B cell tolerance in adenosine deaminase deficiency is corrected by gene therapy. J. Clin. Invest. 122, 2141-2152.
117. Sauer, A. V., Mrak, E., Jofra Hernandez, R., Zacchi, E., Cavani, F., Casiraghi, M., Grunebaum, E., Roifman, C. M., Cervi, M. C., Ambrosi, A., Carlucci, F., Roncarolo, M. G., Villa, A., Rubinacci, A., and Aiuti, A. (2009). ADA-deficient SCID is associated with a specific microenvironment and bone phenotype characterized by RANKL/OPG imbalance and osteoblast insufficiency. Blood 114, 3216-3226.
118. Schenk, U., Frascoli, M., Proietti, M., Geffers, R., Traggiai, E., Buer, J., Ricordi, C., Westendorf, A. M., and Grassi, F. (2011). ATP inhibits the generation and function of regulatory T cells through the activation of purinergic P2X receptors. Sci. Signal. 4, ra12.
119. Schenk, U., Westendorf, A. M., Radaelli, E., Casati, A., Ferro, M., Fumagalli, M., Verderio, C., Buer, J., Scanziani, E., and Grassi, F. (2008). Purinergic control of T cell activation by ATP released through pannexin-1 hemichannels. Sci. Signal. 1, ra6.
120. Sebastiani, G. D., Bottini, N., Greco, E., Saccucci, P., Canu, G., Lucarelli, P., Gloria-Bottini, F., and Fontana, L. (2006). A study of AdenosineDeaminase genetic polymorphism in rheumatoid arthritis. Int. J. Immunopathol. Pharmacol. 23, 791-795.
121. Serana, F., Sottini, A., Chiarini, M., Zanotti, C., Ghidini, C., Lanfranchi, A., Notarangelo, L. D., Caimi, L., and Imberti, L. (2010). The different extent of B and T cell immune reconstitution after hematopoietic stem cell transplantation and enzyme replacement therapies in SCID patients with adenosine deaminase deficiency. J. Immunol. 185, 7713-7722.
122. Shou, Y., Ma, Z., Lu, T., and Sorrentino, B. P. (2006). Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. Proc. Natl. Acad. Sci. U.S.A. 103, 11730-11735.
123. Siaw, M. F., Mitchell, B. S., Koller, C. A., Coleman, M. S., and Hutton, J. J. (1980). ATP depletion as a consequence of adenosine deaminase inhibition in man. Proc. Natl. Acad. Sci. U.S.A. 77, 6157-6161.
124. Simmonds, H. A., Goday, A., Morris, G. S., Fairbanks, L. D., and Levinsky, R. J. (1984). dATP accumulation and ATP depletion in platelets in adenosine deaminase deficiency:significance for the immune response? Biosci. Rep. 4, 809-818.
125. Simmonds, H.A., Levinsky, R. J., Perrett, D., and Webster, D. R. (1982). Reciprocal relationship between erythrocyte ATP and deoxy-ATP levels in inherited ADA deficiency. Biochem. Pharmacol. 31, 947-951.
126. Sitkovsky, M., Lukashev, D., Deaglio, S., Dwyer, K., Robson, S. C., and Ohta, A. (2008). Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells. Br. J. Pharmacol. 153(Suppl. 1), S457- S464.
127. Sitkovsky, M. V., Lukashev, D., Apasov, S., Kojima, H., Koshiba, M., Caldwell, C., Ohta, A., and Thiel, M. (2004). Physiological control of immune response and inflammatory tissue damage by hypoxiainducible factors and adenosine A2A receptors. Annu. Rev. Immunol. 22, 657-682.
128. Skalhegg, B. S., Landmark, B. F., Doskeland, S. O., Hansson, V., Lea, T., and Jahnsen, T. (1992). Cyclic AMPdependent protein kinase type I mediates the inhibitory effects of 3',5'-cyclic adenosine monophosphate on cell replication in human T lymphocytes. J. Biol. Chem. 267, 15707-15714.
129. Titman, P., Pink, E., Skucek, E., O'Hanlon, K., Cole, T. J., Gaspar, J., Xu-Bayford, J., Jones, A., Thrasher, A. J., Davies, E. G., Veys, P. A., and Gaspar, H. B. (2008). Cognitive and behavioral abnormalities in children after hematopoietic stem cell transplantation for severe congenital immunodeficiencies. Blood 112, 3907-3913.
130. Trobridge, G. D. (2011). Genotoxicity of retroviral hematopoietic stem cell gene therapy. Expert Opin. Biol.Ther. 11, 581-593.
131. Utz, P. J., Gensler, T. J., and Anderson, P. (2000). Death, autoantigen modifications, and tolerance. Arthritis Res. 2, 101-114.
132. Van de Wiele, C. J., Joachims, M. L., Fesler, A. M., Vaughn, J. G., Blackburn, M. R., Mcgee, S. T., and Thompson, L. F. (2006). Further differentiation of murine doublepositive thymocytes is inhibited in adenosine deaminase-deficient murine fetal thymic organ culture. J. Immunol. 176, 5925-5933.
133. Van de Wiele, C. J., Vaughn, J. G., Blackburn, M. R., Ledent, C. A., Jacobson, M., Jiang, H., and Thompson, L. F. (2002). Adenosine kinase inhibition promotes survival of fetal adenosine deaminase-deficient thymocytes by blocking dATP accumulation. J. Clin. Invest. 110, 395-402.
134. Vendetti, S., Riccomi, A., Sacchi, A., Gatta, L., Pioli, C., and De Magistris, M. T. (2002). Cyclic adenosine 5'monophosphate and calcium induce CD152 (CTLA-4) up-regulation in resting CD4+ T lymphocytes. J. Immunol. 169, 6231-6235.
135. Vignali, D. A. A., Collison, L. W., and Workman, C. J. (2008). How regulatory T cells work. Nat. Rev. Immunol. 8, 523-532.
136. Waddell, D., and Ullman, B. (1983). Characterization of a cultured human T-cell line with genetically altered ribonucleotide reductase activity. Model for immunodeficiency. J. Biol. Chem. 258, 4226-4231.
137. Waldner, H., Collins, M., and Kuchroo, V. K. (2004). Activation of antigenpresenting cells by microbial products breaks self tolerance and induces autoimmune disease. J. Clin. Invest. 113, 990-997.
138. Wardemann, H., and Nussenzweig, M. C. (2007). B-cell self-tolerance in humans. Adv. Immunol. 95, 83-110.
139. Wardemann, H., Yurasov, S., Schaefer, A., Young, J. W., Meffre, E., and Nussenzweig, M. C. (2003). Predominant autoantibody production by early human B cell precursors. Science 301, 1374-1377.
140. Weinberg, K., Hershfield, M. S., Bastian, J., Kohn, D., Sender, L., Parkman, R., and Lenarsky, C. (1993). T lymphocyte ontogeny in adenosine deaminase-deficient severe combined immune deficiency after treatment with polyethylene glycol-modified adenosine deaminase. J. Clin. Invest. 92, 596-602.
141. Westerberg, L. S., Klein, C., and Snapper, S. B. (2008). Breakdown of T cell tolerance and autoimmunity in primary immunodeficiency - lessons learned from monogenic disorders in mice and men. Curr. Opin. Immunol. 20, 646-654.
142. Yip, L., Woehrle, T., Corriden, R., Hirsh, M., Chen, Y., Inoue, Y., Ferrari, V., Insel, P. A., and Junger, W. G. (2009). Autocrine regulation of T-cell activation by ATP release and P2×7 receptors. FASEB J. 23, 1685-1693.
143. Zarek, P. E., Huang, C. T., Lutz, E. R., Kowalski, J., Horton, M. R., Linden, J., Drake, C. G., and Powell, J. D. (2008). A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood 111, 251-259.